Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,253.9
6.8 (0.21%)

 

  • STI Straits Times Index
    3,253.9
    6.8 (0.21%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,578.0
    -9.3 (-0.59%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,341.0
    355.7 (1.27%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,060.8
    8.6 (0.28%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    24,031.3
    166.8 (0.70%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,233.5
    -4.7 (-0.08%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,267.2
    27.6 (1.23%)
    Index delayed 20 minutes
  • XAO XAO
    7,249.0
    68.5 (0.95%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,638.5M
  • Value: 1,045.8M
  • Rise: 151
  • Fall: 154
  • Unch: 514

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Medtecs Intl0.098+0.006
AsiaMedic0.016-0.002
Healthway Med0.043+0.003
P5 Capital0.033-0.002
Ntegrator Intl0.015+0.002
AusGroup^0.044-0.001
YZJ Shipbldg SGD1.090-0.010
Thomson Medical0.064+0.001
DISA0.002-0.001
Golden Agri-Res0.230-

World Indices

World Indices
Name Last Change
Nasdaq 9,370.8 -18.1
HSI 28,341.0 +355.7
HSCEI 11,174.7 +204.6
Jakarta 6,233.5 -4.7
Nikkei 225 24,031.3 +166.8
SSE Comp 3,060.8 +8.6
Shanghai A 3,207.1 +9.0
Shanghai B 257.5 +0.2
PSE Comp 0.0
KOSPI 2,267.2 +27.6

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

IBIO INC IBIO
Updated on 21 Jan 2020 (End of trading day)
Last (USD): 0.320 Change: +0.085 High: 0.320 Remarks: -
Change (%): +36.23 Low: 0.242
Open 0.260 Yesterday's Close 0.2349
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 27,499,210 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.19234 Trailing EPS (USD) e -0.19304 NAV (USD) b -0.0208
PE a - Trailing PE f - Price / NAV b -15.3846
Dividend (USD) d - Cash In Hand (USD) g 0.0227 Issued & Paid-up Shares c 59,327,500
Dividend Yield (%) d - Price / Cash In Hand g 14.097 Treasury Shares h -
Beta - 75 Daysi -0.008 R-Squared - 75 Days(%)i - Market Cap (M) 29.702
Beta - 500 Daysi 0.292 R-Squared - 500 Days (%)i 0.01 Enterprise Value (M) 59.966
Piotroski F Score 1 Exchange Code IBIO Par Value ( $ ) n.a.
52 Weeks Volatility (%) 148.65 Free Float (%) 48.7
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 15 Jan 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 29 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference IBIO INC NYSE American 29.702 - - -15.3846 -
Industry Biotechnology NYSE American 105.876 - - 4.0234 -
Local Peer NANOVIRICIDES INC NYSE American 536.112 - - 58.7422 -
Local Peer PFENEX INC NYSE American 257.878 - - 4.6186 -
Local Peer NAVIDEA BIOPHARMACEUTICALS INC NYSE American 227.090 - - -297.8723 -
Local Peer MATINAS BIOPHARMA HOLDINGS INC NYSE American 143.476 - - 4.2254 -
Local Peer LINEAGE CELL THERAPEUTICS INC NYSE American 127.475 - - 1.0881 -
Local Peer CEL-SCI CORP NYSE American 115.113 - - 22.4223 -
Local Peer 22ND CENTURY GROUP INC NYSE American 112.008 - - 2.0253 -
Local Peer PALATIN TECHNOLOGIES INC NYSE American 107.725 3.011 2.915 1.1206 -
Local Peer SYNTHETIC BIOLOGICS INC NYSE American 70.408 - - 686.2500 -
Local Peer ISORAY INC NYSE American 54.467 - - 7.8323 -
Local Peer ARMATA PHARMACEUTICALS INC NYSE American 30.464 - - 1.6801 -
Local Peer ORAGENICS INC NYSE American 22.365 - - 1.5636 -
Other Local Peers ACTINIUM PHARMACEUTICALS INC (NYSE American), INDIA GLOBALIZATION CAPITAL INC (NYSE American), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), NOVABAY PHARMACEUTICALS INC (NYSE American), AIM IMMUNOTECH INC (NYSE American)
Global Peer AMGEN INC NASDAQ 141,178.118 16.819 17.501 12.9201 2.355
Global Peer CSL ASX 140,022.597 52.190 52.190 18.7117 0.860
Global Peer GILEAD SCIENCES INC NASDAQ 79,236.345 14.525 29.423 3.8457 3.689
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer VERTEX PHARMACEUTICAL NASDAQ 60,170.529 28.702 28.068 11.4536 -
Global Peer BIOGEN INC NASDAQ 51,821.138 11.696 9.604 3.7026 -
Global Peer ILLUMINA INC NASDAQ 48,264.510 58.432 49.604 10.8728 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 39,933.892 16.337 18.624 3.8016 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,795.499 87.961 25.953 5.8541 0.682
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 25,008.096 322.269 17.009 2.4122 -
Other Global Peers SINO BIOPHARM (HKEx), SEATTLE GENETICS INC (NASDAQ), WUXI BIO (HKEx), INCYTE CORPORATION (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), BEIGENE (HKEx), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), REPLIGEN CORP (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), Lonza (SGX), GENSCRIPT BIO (HKEx), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), IMMUNOMEDICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), 3SBIO (HKEx), FIBROGEN INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ALKERMES PLC (NASDAQ), NATERA INC (NASDAQ), ACCELERON PHARMA (NASDAQ), KODIAK SCIENCES INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), EPIZYME INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), XENCOR INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), VIELA BIO INC (NASDAQ), INSMED INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), HAOHAI BIOTEC (HKEx), ALPHAMAB-B (HKEx), REGENXBIO INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), CORTEXYME INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ALECTOR INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), NEXTCURE INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), NGM BIOPHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), POLYNOVO LIMITED (ASX), ENANTA PHARMACEUTICALS INC (NASDAQ), FRONTAGE (HKEx), KARYOPHARM THERAPEUTICS INC (NASDAQ), CKLIFE SCIENCES (HKEx), NANOSTRING TECHNOLOGIES INC (NASDAQ), AVITA MEDICAL LTD (ASX), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), OPKO HEALTH INC (NASDAQ), DERMIRA INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), MESOBLAST LTD (ASX), SANGAMO THERAPEUTICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), RADIUS HEALTH INC (NASDAQ), VIVA BIOTECH (HKEx), ACHILLION PHARMACEUTICALS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), ASCENTAGE-B (HKEx), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), KADMON HLDGS INC (NYSE), HOMOLOGY MEDICINES INC (NASDAQ), OMEROS CORP (NASDAQ), CYTOKINETICS INC (NASDAQ), AVROBIO INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), IMMUNOGEN INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), ARDELYX INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), MACROGENICS INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), KURA ONCOLOGY INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), AGENUS INC (NASDAQ), SINOMAB BIO-B (HKEx), VIKING THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), TRANSLATE BIO INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), BIOCRYST PHARMACEUTICALS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), ASCLETIS-B (HKEx), ESSEX BIO-TECH (HKEx), ANAPTYSBIO INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), CABALETTA BIO INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), RECRO PHARMA INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), PERSONALIS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), LEE'S PHARM (HKEx), CYTOMX THERAPEUTICS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), NOVAVAX INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), MEDICINOVA INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), GERON CORP (NASDAQ), DPHARMA (Bursa), KAMADA (NASDAQ), NEXT SCIENCE LTD (ASX), WAVE LIFE SCIENCES LTD (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), TELIX PHARMACEUTIC (ASX), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), SERES THERAPEUTICS (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), BBI LIFE SCI (HKEx), SYNDAX PHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), AFFIMED N V (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), XOMA CORP (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), IMV INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), ATHERSYS INC (NASDAQ), CHIASMA INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), PROTAGONIST THERAPEUTICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), ARAVIVE INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), CONTRAFECT CORP (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), SAVARA INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), AVALON GLOBOCARE CORP (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), VERASTEM INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), NEUROBO PHARMACEUTICALS INC (NASDAQ), CHIMERIX INC (NASDAQ), UNI-BIO GROUP (HKEx), FENNEC PHARMACEUTICALS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), ENZO BIOCHEM INC (NYSE), HARVARD BIOSCIENCE INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), ADURO BIOTECH INC (NASDAQ), OTONOMY INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), IMUGENE LIMITED (ASX), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), SYNLOGIC INC (NASDAQ), COHBAR INC (NASDAQ), SESEN BIO INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), INFLARX N V (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), NEWLINK GENETICS CORP (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ORGENESIS INC (NASDAQ), TREVENA INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), IMMUTEP LTD (ASX), CATABASIS PHARMACEUTICALS INC (NASDAQ), VERMILLION INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), VACCINEX INC (NASDAQ), EQUILLIUM INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), ALPINE IMMUNE SCIENCES INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), ORTHOCELL LIMITED (ASX), GENOCEA BIOSCIENCES INC (NASDAQ), INMUNE BIO INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), CURIS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), RESTORBIO INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), ADVAXIS INC (NASDAQ), CT ENTERPRISE (HKEx), DIAMEDICA THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), SOLIGENIX INC (NASDAQ), ZAFGEN INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), MERRIMACK PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), BIOSINO BIO-TEC (HKEx), CELLDEX THERAPEUTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), OCUGEN INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), ANTEOTECH LIMITED (ASX), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), VISTAGEN THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), REGENT PACIFIC (HKEx), MEMPHASYS LTD (ASX), BIOTRON (ASX), AETERNA ZENTARIS INC (NASDAQ), BIONOMICS LTD (ASX), ACTINOGEN MEDICAL LTD (ASX), GENETIC TECHNOLOGIES (ASX), TALI DIGITAL LIMITED (ASX), VAXART INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), ATYR PHARMA INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), EXTRAWELL PHAR (HKEx), BIO-PATH HOLDINGS INC (NASDAQ), RHINOMED LIMITED (ASX), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), CCP TECHNOLOGIES LTD (ASX), MIRAGEN THERAPEUTICS INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), PRECIPIO INC (NASDAQ), SENESTECH INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), PATRYS LIMITED (ASX), TRACON PHARMACEUTICALS INC (NASDAQ), CELLMID LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), CONATUS PHARMACEUTICALS INC (NASDAQ), BIOCEPT INC (NASDAQ), TOCAGEN INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), Suntar Eco-City^ (SGX), REGENEUS LTD (ASX), CYCLACEL PHARMA IN (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), ACHIEVE LIFE SCIENCE INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), TROVAGENE INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), ADALTA LTD (ASX), OPGEN INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), SIENNA CANCER DIAGNOSTICS LTD (ASX), ARCA BIOPHARMA INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), BENITEC BIOPHARMA LTD (ASX), BIOXYNE LIMITED (ASX), CAPRICOR THERAPEUTICS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), AUSTRALIAN PRIMARY HEMP LTD (ASX), HAO WEN HLDGS (HKEx), LIVING CELL TECHNOLOGIES (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), MEDIBIO LIMITED (ASX), QT Vascular (SGX), PHIO PHARMACEUTICALS CORP (NASDAQ), MGRC (Bursa), SPHERIX INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), TBG DIAGNOSTICS LTD (ASX), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), BPH ENERGY LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.097
+43.50 %
10 Days -+0.041
+14.70 %
20 Days -+0.082
+34.45 %
Medium Term Return 3 Months --0.155
-32.63 %
6 Months --0.370
-53.62 %
1 Year --0.537
-62.66 %
Long Term Return 2 Years --1.481
-82.23 %
3 Years --3.680
-92.00 %
5 Years --4.180
-92.89 %
Annualised Return Annualised --
-41.06 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.050 - 1.400 Change From 1 Year Low +0.270 % Change From 1 Year Low (%) +540.00
Change From 1 Year High -1.080 % Change From 1 Year High (%) -77.14
2 Years Range 0.050 - 3.497 Change From 2 Years Low +0.270 % Change From 2 Years Low (%) +540.00
Change From 2 Years High -3.177 % Change From 2 Years High (%) -90.85
5 Years Range 0.050 - 13.200 Change From 5 Years Low +0.270 % Change From 5 Years Low (%) +540.00
Change From 5 Years High -12.880 % Change From 5 Years High (%) -97.58
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. It operates through the iBio, Inc. and iBio CDMO business segments. The company was founded on April 15, 1993 and is headquartered in New York, NY.

Historical Price Data

Date Open High Low Close Volume VWAP
21 Jan 2020 0.260 0.320 0.242 0.320 27,499,210 -
17 Jan 2020 0.250 0.250 0.230 0.235 3,306,255 -
16 Jan 2020 0.250 0.260 0.235 0.242 8,010,769 -
15 Jan 2020 0.224 0.235 0.220 0.223 2,671,962 -
14 Jan 2020 0.235 0.237 0.225 0.226 2,891,973 -
13 Jan 2020 0.260 0.260 0.210 0.229 9,663,115 -
10 Jan 2020 0.265 0.281 0.260 0.270 3,186,285 -
09 Jan 2020 0.280 0.280 0.250 0.265 3,044,922 -
08 Jan 2020 0.250 0.285 0.232 0.279 5,727,732 -
07 Jan 2020 0.270 0.280 0.250 0.260 5,727,087 -
06 Jan 2020 0.322 0.343 0.261 0.277 19,400,500 -
03 Jan 2020 0.310 0.335 0.280 0.313 12,190,400 -
02 Jan 2020 0.264 0.310 0.246 0.296 12,400,810 -
31 Dec 2019 0.241 0.260 0.240 0.249 3,629,280 -
30 Dec 2019 0.240 0.263 0.230 0.248 5,715,625 -
27 Dec 2019 0.230 0.240 0.220 0.232 2,782,340 -
26 Dec 2019 0.230 0.239 0.222 0.232 2,194,463 -
24 Dec 2019 0.245 0.245 0.230 0.238 1,621,860 -
23 Dec 2019 0.245 0.270 0.231 0.245 6,312,838 -
20 Dec 2019 0.220 0.270 0.205 0.270 3,512,676 -
19 Dec 2019 0.219 0.219 0.205 0.215 2,494,945 -
18 Dec 2019 0.225 0.238 0.214 0.220 5,162,754 -
Summary
Current 2 Weeks
(07 Jan 2020 to 21 Jan 2020)
0.270 0.320 0.210 0.320 71,729,310 -
Previous 2 Weeks
(20 Dec 2019 to 06 Jan 2020)
0.220 0.320 0.205 0.277 69,760,792 -
4 Weeks from
(21 Nov 2019 to 19 Dec 2019)
0.115 0.320 0.110 0.215 228,109,525 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.